Indivior Announces Q1 2024 Financial Results

SLOUGH, United Kingdom and RICHMOND, Va., April 25, 2024

• The earnings release can be found at www.indivior.com/investors
• The investor presentation can be found at www.indivior.com/investors (at 7:00 am EST)

There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below.

Webcast link: https://edge.media-server.com/mmc/p/hktzzit4
Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI2351ee9819db40d1a28c31f75cece519

(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration) 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior. 

Logo - https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg